Published in Cancer Weekly, August 5th, 2003
The first patent granted in the U.S. that claims an ISS alone as a composition of matter, the '940 patent gives Dynavax an important position in the rapidly developing field of ISS-based immunoregulatory agents. Dynavax employs the 1018 ISS molecule in four product candidates currently in clinical trials for allergy, asthma, hepatitis B, and cancer.
ISS are short synthetic DNA sequences containing a CpG dinucleotide that have been shown to act as signaling...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.